Evidence map›Paper›PMID 36860850›Full record

ArticleFrontiers in immunology2023

Persistent memory despite rapid contraction of circulating T Cell responses to SARS-CoV-2 mRNA vaccination.

Ellie Taus, Christian Hofmann, F Javier Ibarrondo, Laura S Gong, Mary Ann Hausner, Jennifer A Fulcher, Paul Krogstad, Scott G Kitchen, Kathie G Ferbas, Nicole H Tobin and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. The molecular mechanisms of CD8Frontiers in immunology · 2024
    Review
  7. Predominantly defective CD8Journal of translational medicine · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

Ellie TausDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Christian HofmannDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
F Javier IbarrondoDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Laura S GongDepartment of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Mary Ann HausnerDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Jennifer A FulcherDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Paul KrogstadDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.
Scott G KitchenDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Kathie G FerbasDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Nicole H TobinDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Anne W RimoinFielding School of Public Health, University of California Los Angeles, Los Angeles, CA, United States.
Grace M AldrovandiDepartment of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
Otto O YangDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, United States.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: While antibodies raised by SARS-CoV-2 mRNA vaccines have had compromised efficacy to prevent breakthrough infections due to both limited durability and spike sequence variation, the vaccines have remained highly protective against severe illness. This protection is mediated through cellular immunity, particularly CD8+ T cells, and lasts at least a few months. Although several studies have documented rapidly waning levels of vaccine-elicited antibodies, the kinetics of T cell responses have not been well defined. Methods: Interferon (IFN)-γ enzyme-linked immunosorbent spot (ELISpot) assay and intracellular cytokine staining (ICS) were utilized to assess cellular immune responses (in isolated CD8+ T cells or whole peripheral blood mononuclear cells, PBMCs) to pooled peptides spanning spike. ELISA was performed to quantitate serum antibodies against the spike receptor binding domain (RBD). Results: In two persons receiving primary vaccination, tightly serially evaluated frequencies of anti-spike CD8+ T cells using ELISpot assays revealed strikingly short-lived responses, peaking after about 10 days and becoming undetectable by about 20 days after each dose. This pattern was also observed in cross-sectional analyses of persons after the first and second doses during primary vaccination with mRNA vaccines. In contrast, cross-sectional analysis of COVID-19-recovered persons using the same assay showed persisting responses in most persons through 45 days after symptom onset. Cross-sectional analysis using IFN-γ ICS of PBMCs from persons 13 to 235 days after mRNA vaccination also demonstrated undetectable CD8+ T cells against spike soon after vaccination, and extended the observation to include CD4+ T cells. However, ICS analyses of the same PBMCs after culturing with the mRNA-1273 vaccine in vitro showed CD4+ and CD8+ T cell responses that were readily detectable in most persons out to 235 days after vaccination. Discussion: Overall, we find that detection of spike-targeted responses from mRNA vaccines using typical IFN-γ assays is remarkably transient, which may be a function of the mRNA vaccine platform and an intrinsic property of the spike protein as an immune target. However, robust memory, as demonstrated by capacity for rapid expansion of T cells responding to spike, is maintained at least several months after vaccination. This is consistent with the clinical observation of vaccine protection from severe illness lasting months. The level of such memory responsiveness required for clinical protection remains to be defined.

Indexed as

COVID-19SARS-CoV-22019-nCoV Vaccine mRNA-1273Antibodies, ViralCross-Sectional StudiesCytokinesEnzyme-Linked Immunospot AssayHumansLeukocytes, MononuclearVaccination2019-nCoV Vaccine mRNA-1273Antibodies, ViralCytokinescellular immunityelispotintracellular cytokine stainingSARS-CoV-2SARS-CoV-2 mRNA vaccinesT cell memoryT cells

Identifiers

PMID36860850
PMCPMC9968837
OpenAlexW4320495653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.